Welcome to our dedicated page for OPKO HEALTH SEC filings (Ticker: OPK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on OPKO HEALTH's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into OPKO HEALTH's regulatory disclosures and financial reporting.
OPKO HEALTH, INC. director John A. Paganelli received a grant of stock options for 30,000 shares of common stock as compensation. The options have an exercise price of $1.42 per share, become exercisable starting on 2027-06-18, and expire on 2036-06-17. Following this grant, he holds 30,000 options directly.
OPKO HEALTH, INC. director Richard C. Pfenniger Jr. received a grant of stock options representing 60,000 shares of common stock. The options have an exercise price of $1.42 per share, become exercisable on June 18, 2027, and expire on June 17, 2036. After this award, he holds 60,000 derivative securities directly.
OPKO HEALTH director Uppaluri Subbarao V received a grant of stock options covering 80,000 shares of common stock as part of standard director compensation. The options have an exercise price of $1.42 per share, become exercisable on June 18, 2027, and expire on June 17, 2036.
According to the footnote, on June 18, 2026 the company canceled a prior grant of 50,000 options, granted 30,000 new options, and reissued 50,000 options, resulting in 80,000 options held directly after this award.
OPKO HEALTH, INC. director Alice Lin-Tsing Yu received a grant of stock options covering 30,000 shares of common stock. The options have an exercise price of $1.42 per share, were granted on June 18, 2026, and become exercisable starting June 18, 2027 with an expiration date of June 17, 2036. Following this grant, she holds stock options for 30,000 shares directly.
OPKO Health, Inc. reported the results of its 2026 Annual Meeting of Stockholders held on June 18, 2026. Stockholders elected eleven directors, each receiving more votes "For" than "Against", including Phillip Frost, M.D. with 423,666,978 votes for and 40,175,942 against.
Stockholders approved the Company’s 2026 Equity Incentive Plan, with 440,096,997 votes for and 23,694,041 against. They also approved, on a non-binding advisory basis, the compensation of the named executive officers, with 446,238,170 votes for and 17,487,326 against.
In addition, stockholders ratified the appointment of Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026, with 535,070,921 votes for and 6,120,699 against. No other matters were considered or voted upon at the meeting.
OPKO Health is calling a virtual 2026 annual stockholder meeting on June 18, 2026, asking investors to elect 11 directors, approve a new 2026 Equity Incentive Plan, give an advisory Say on Pay vote, and ratify Ernst & Young LLP as auditor for 2026.
Stockholders of record on April 20, 2026, holding 755,092,256 outstanding common shares, are entitled to one vote per share and may vote online, by phone, or by mail. The proxy details a board where independent directors form a majority and chair all key committees, and shows significant insider and large‑holder ownership, including 33.31% beneficial ownership by CEO Phillip Frost, M.D.
OPKO Health reported first‑quarter 2026 revenue of $124.2M, down from $150.0M a year earlier, as service revenue declined while product and intellectual property revenue grew modestly. Total costs and expenses fell to $175.2M, improving the operating loss to $51.0M from $67.2M.
Net loss narrowed to $54.8M, or $0.07 per share, compared with a $67.6M loss, or $0.10 per share, in the prior‑year quarter. Cash, cash equivalents and restricted cash were $355.6M at March 31, 2026, with net cash used in operating activities improving to $19.3M from $34.6M.
Total assets were $1.86B and total liabilities $652.2M, leaving shareholders’ equity of $1.20B. The company continued its repurchase program, buying 3.95M shares for about $4.8M in the quarter, and remains exposed to foreign exchange movements, with 32.7% of revenue in non‑U.S. currencies.
OPKO Health reported first quarter 2026 results showing lower revenue but narrower losses as it reshapes its business. Total revenue was $124.2 million versus $149.9 million a year earlier, largely reflecting the prior sale of certain BioReference oncology assets.
Operating loss improved to $51.0 million from $67.2 million, and net loss narrowed to $54.8 million, or $0.07 per share, compared with a net loss of $67.6 million, or $0.10 per share. Pharmaceuticals revenue grew to $52.0 million, helped by higher international sales and increased NGENLA profit share, while diagnostics revenue declined to $72.2 million after the oncology divestiture.
Cash, cash equivalents, marketable securities and restricted cash totaled $341.9 million as of March 31, 2026. The company repurchased approximately $92.0 million of stock since its July 2025 authorization, including $4.8 million in the quarter, with about $108.0 million remaining available.
Opko Health director John A. Paganelli bought 10,000 shares of common stock in an open-market purchase at $1.135 per share. After this transaction, he directly holds 394,340 shares. An additional 9,175 shares are owned by his spouse, for which he disclaims beneficial ownership except for any pecuniary interest.